Literature DB >> 32976738

Models of Idiosyncratic Drug-Induced Liver Injury.

Tsuyoshi Yokoi1, Shingo Oda1.   

Abstract

Drug-induced liver injury (DILI) is a leading cause of attrition during the early and late stages of drug development and after a drug is marketed. DILI is generally classified as either intrinsic or idiosyncratic. Intrinsic DILI is dose dependent and predictable (e.g., acetaminophen toxicity). However, predicting the occurrence of idiosyncratic DILI, which has a very low incidence and is associated with severe liver damage, is difficult because of its complex nature and the poor understanding of its mechanism. Considering drug metabolism and pharmacokinetics, we established experimental animal models of DILI for 14 clinical drugs that cause idiosyncratic DILI in humans, which is characterized by the formation of reactive metabolites and the involvement of both innate and adaptive immunity. On the basis of the biomarker data obtained from the animal models, we developed a cell-based assay system that predicts the potential risks of drugs for inducing DILI. These findings increase our understanding of the mechanisms of DILI and may help predict and prevent idiosyncratic DILI due to certain drugs.

Entities:  

Keywords:  DILI; animal models; drug-induced liver injury; idiosyncratic DILI; immune and inflammatory responses; in vitro cell-based assay; reactive metabolites

Year:  2020        PMID: 32976738     DOI: 10.1146/annurev-pharmtox-030220-015007

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  7 in total

Review 1.  Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Authors:  Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 11.413

2.  Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury.

Authors:  Robert A Roth; Omar Kana; David Filipovic; Patricia E Ganey
Journal:  Expert Opin Drug Metab Toxicol       Date:  2022-08-24       Impact factor: 4.936

3.  Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data.

Authors:  Jaydeep Yadav; Mehdi El Hassani; Jasleen Sodhi; Volker M Lauschke; Jessica H Hartman; Laura E Russell
Journal:  Drug Metab Rev       Date:  2021-05-25       Impact factor: 6.984

4.  Testing Possible Risk Factors for Idiosyncratic Drug-Induced Liver Injury Using an Amodiaquine Mouse Model and Co-treatment with 1-Methyl-d-Tryptophan or Acetaminophen.

Authors:  Tiffany Cho; Lie Yun Kok; Jack Uetrecht
Journal:  ACS Omega       Date:  2021-02-07

5.  Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury.

Authors:  Min Liu; Qiong Huang; Yan Zhu; Li Chen; Yumei Li; Zhicheng Gong; Kelong Ai
Journal:  Mater Today Bio       Date:  2022-02-08

6.  Hepatoprotective potential of a novel quinazoline derivative in thioacetamide-induced liver toxicity.

Authors:  Suzy Salama; Chin Siang Kue; Haryanti Mohamad; Fatima Omer; Mohamed Yousif Ibrahim; Mahmood Abdulla; Hapipah Ali; Abdalbasit Mariod; Soher Nagi Jayash
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

7.  Acute liver failure in Still's disease relapse during pregnancy: case report and discussion of a possible trigger role of DILI.

Authors:  Giuseppe Marrone; Francesco Galati; Marco Biolato; Cristopher Oddy; Sara De Carolis; Angelo Zoli; Antonio Grieco
Journal:  BMC Gastroenterol       Date:  2021-08-06       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.